These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 20669328)

  • 1. H1N1 influenza virus-like particles: physical degradation pathways and identification of stabilizers.
    Kissmann J; Joshi SB; Haynes JR; Dokken L; Richardson C; Middaugh CR
    J Pharm Sci; 2011 Feb; 100(2):634-45. PubMed ID: 20669328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formulation development of a plant-derived H1N1 influenza vaccine containing purified recombinant hemagglutinin antigen.
    Iyer V; Liyanage MR; Shoji Y; Chichester JA; Jones RM; Yusibov V; Joshi SB; Middaugh CR
    Hum Vaccin Immunother; 2012 Apr; 8(4):453-64. PubMed ID: 22370514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plant-made virus-like particles bearing influenza hemagglutinin (HA) recapitulate early interactions of native influenza virions with human monocytes/macrophages.
    Makarkov AI; Chierzi S; Pillet S; Murai KK; Landry N; Ward BJ
    Vaccine; 2017 Aug; 35(35 Pt B):4629-4636. PubMed ID: 28712489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antigenic stability of H1N1 pandemic vaccines correlates with vaccine strain.
    Farnsworth A; Cyr TD; Li C; Wang J; Li X
    Vaccine; 2011 Feb; 29(8):1529-33. PubMed ID: 21211583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemical composition of haemagglutinin-based influenza virus-like particle vaccine produced by transient expression in tobacco plants.
    Le Mauff F; Mercier G; Chan P; Burel C; Vaudry D; Bardor M; Vézina LP; Couture M; Lerouge P; Landry N
    Plant Biotechnol J; 2015 Jun; 13(5):717-25. PubMed ID: 25523794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influenza virus-like particle can accommodate multiple subtypes of hemagglutinin and protect from multiple influenza types and subtypes.
    Pushko P; Pearce MB; Ahmad A; Tretyakova I; Smith G; Belser JA; Tumpey TM
    Vaccine; 2011 Aug; 29(35):5911-8. PubMed ID: 21723354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.
    Bright RA; Carter DM; Daniluk S; Toapanta FR; Ahmad A; Gavrilov V; Massare M; Pushko P; Mytle N; Rowe T; Smith G; Ross TM
    Vaccine; 2007 May; 25(19):3871-8. PubMed ID: 17337102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influenza-pseudotyped Gag virus-like particle vaccines provide broad protection against highly pathogenic avian influenza challenge.
    Haynes JR; Dokken L; Wiley JA; Cawthon AG; Bigger J; Harmsen AG; Richardson C
    Vaccine; 2009 Jan; 27(4):530-41. PubMed ID: 19026705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inactivated seasonal influenza vaccines increase serum antibodies to the neuraminidase of pandemic influenza A(H1N1) 2009 virus in an age-dependent manner.
    Sambhara V
    J Infect Dis; 2011 Jun; 203(11):1697-8. PubMed ID: 21593002
    [No Abstract]   [Full Text] [Related]  

  • 10. A pandemic H1N1 influenza virus-like particle vaccine induces cross-protection in mice.
    Inn KS; Lee GJ; Quan FS
    Immunol Invest; 2014; 43(3):236-54. PubMed ID: 24354853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention: Vaccine for all seasons.
    Schlütter J
    Nature; 2011 Nov; 480(7376):S6-8. PubMed ID: 22158298
    [No Abstract]   [Full Text] [Related]  

  • 12. Formulation Studies During Preclinical Development of Influenza Hemagglutinin and Virus-Like Particle Vaccine Candidates.
    Wahome N; Hickey JM; Volkin DB; Middaugh CR
    Methods Mol Biol; 2016; 1404():393-421. PubMed ID: 27076313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protection of pigs against pandemic swine origin H1N1 influenza A virus infection by hemagglutinin- or neuraminidase-expressing attenuated pseudorabies virus recombinants.
    Klingbeil K; Lange E; Blohm U; Teifke JP; Mettenleiter TC; Fuchs W
    Virus Res; 2015 Mar; 199():20-30. PubMed ID: 25599604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physical stabilization of Norwalk virus-like particles.
    Kissmann J; Ausar SF; Foubert TR; Brock J; Switzer MH; Detzi EJ; Vedvick TS; Middaugh CR
    J Pharm Sci; 2008 Oct; 97(10):4208-18. PubMed ID: 18300304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Formulation design and high-throughput excipient selection based on structural integrity and conformational stability of dilute and highly concentrated IgG1 monoclonal antibody solutions.
    Bhambhani A; Kissmann JM; Joshi SB; Volkin DB; Kashi RS; Middaugh CR
    J Pharm Sci; 2012 Mar; 101(3):1120-35. PubMed ID: 22147527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sensitivity of immune response quality to influenza helix 190 antigen structure displayed on a modular virus-like particle.
    Anggraeni MR; Connors NK; Wu Y; Chuan YP; Lua LH; Middelberg AP
    Vaccine; 2013 Sep; 31(40):4428-35. PubMed ID: 23845811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant H1N1 virus-like particle vaccine elicits protective immunity in ferrets against the 2009 pandemic H1N1 influenza virus.
    Pushko P; Kort T; Nathan M; Pearce MB; Smith G; Tumpey TM
    Vaccine; 2010 Jul; 28(30):4771-6. PubMed ID: 20470801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of H1N1 influenza virus-like particles produced in Nicotiana benthamiana.
    Shoji Y; Prokhnevsky A; Leffet B; Vetter N; Tottey S; Satinover S; Musiychuk K; Shamloul M; Norikane J; Jones RM; Chichester JA; Green BJ; Streatfield SJ; Yusibov V
    Hum Vaccin Immunother; 2015; 11(1):118-23. PubMed ID: 25483524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The osmotic stress response of split influenza vaccine particles in an acidic environment.
    Choi HJ; Kim MC; Kang SM; Montemagno CD
    Arch Pharm Res; 2014 Dec; 37(12):1607-16. PubMed ID: 24101412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stabilization of HAC1 influenza vaccine by spray drying: formulation development and process scale-up.
    Zhu C; Shoji Y; McCray S; Burke M; Hartman CE; Chichester JA; Breit J; Yusibov V; Chen D; Lal M
    Pharm Res; 2014 Nov; 31(11):3006-18. PubMed ID: 24858396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.